The Clinical Research of Expression and Correlation of Survivin and HSP70 in Bladder Transitional Cell Carcinoma

Objective: To explore survivin and HSP70 expression in bladder transitional cell carcinoma (bladder transitional cell carcinoma, BTCC) and its expression correlation to look for early diagnosis, to determine the prognostic value of tumor markers, to take timely and reasonable treatment, improve the overall survival of patients with bladder cancer. Methods: Immunohistochemical SP (streptavidin-peroxidase, streptavidin-biotin - peroxidase) method on the surgical removal of the Second Hospital of Hebei Medical University from October 2006 to August 2007 and confirmed by pathology data 48 cases of BTCC complete specimens and 13 normal bladder tissue samples were Survivin and detection of HSP70 expression as well as with the BTCC clinicopathological features, and both, both expressed in the BTCC conducted a statistical analysis. SPSS13.0 statistical package for statistical analysis. In alpha = 0.05 as the significance level of the statistical test. Results: Survivin protein in 13 cases of normal bladder tissue does not express, in 48 cases of BTCC organizations have 37 cases of expression of positive, accounting for 77.08% (37/48), the difference was significant significance (P lt; 0.01); HSP70 protein positive expression rate was 15.38% (2/13), in 13 cases of normal bladder tissue in 48 BTCC tissues, 27 cases were positive, accounting for 56.25% (27/48), the difference was significant (P lt; 0.01 ). Survivin positive expression rate between different age, gender, tumor size and the number of patients, no significant difference (P gt; 0.05); Survivin protein expression rate and intensity increased with increasing pathological grade, I, II, III level BTCC, abnormal expression rate was 42.86% (6/14), 88% (22/25), 100% (9/9), the difference has a significant meaning (P lt; 0.01). As the BTCC clinical stage increased, the expression of Survivin protein is rising, in Ta-T (superficial) and T2-T4 (infiltration) abnormal expression rate were 60% (15/25), 95.65% (22/23), and the difference was significant (P lt; 0.01). Survivin protein abnormal expression in the primary group was 50% (9/18), and the abnormal expression of the recurrent group was 93.33% (28/30), the difference was significant (P lt; 0.01) HSP70 positive expression rate between different age, gender, tumor size and the number of patients, no significant difference (P gt; 0.05); HSP70 protein expression rate and intensity increased with increasing pathological grade, I , II, III level BTCC, abnormal expression rate of 28.57% (4/14), 64.00% (16/25), 77.78% (7/9), and the difference was significant (P lt; 0.01). With the BTCC clinical stage increased HSP70 protein expression upward trend in Ta-T1 (superficial) and T ₂ -T ₄ (invasive) The abnormal expression rate was 36.00% (9/25), 78.26% (18/23), and the difference was significant (P lt; 0.01). HSP70 protein in the primary group, abnormal expression rate of 27.78% (5/18), the abnormal expression of the recurrent group was 73.33% (22/30), the difference between the two groups was significant (P lt; 0.01) . 48 BTCC tissues, survivin and HSP70 in both co-expression was positive in 25 cases, 9 were negative co-expression, the expression of both bladder transitional cell carcinoma in a positive correlation (Pearson column contact = 0.3457, P lt; 0.05). Conclusion: Survivin and HSP70 in bladder cancer specific upregulation involved in the occurrence and development of bladder cancer. Survivin and HSP70 expression with tumor grade, clinical stage and increased tumor recurrence and raised to become an important indicator of the degree of malignancy of the forecast bladder cancer. Survivin and HSP70 expression in bladder cancer was a positive correlation between the two may be a better indicator of early diagnosis and prediction of recurrence of bladder tumors, but also is expected to become a new way to targeted therapy of bladder cancer.